Memo Therapeutics AG

Memo Therapeutics AG

Biotechnologieforschung

Schlieren, Zurich 4.467 Follower:innen

Info

Memo Therapeutics AG (“MTx”) is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Company’s lead program, Potravitug, is in Phase II development targeting BK viremia (BKV) in kidney transplant recipients, an infection which can result in decreased kidney functionality and longevity and reduced patient survival. Potravitug has the potential to become the best and first-in-class BKV disease-modifying therapy for kidney transplant patients. Alongside Potravitug, MTx is focused on discovering novel antibody-target pairs for oncology based on tumor infiltrating B-cells derived leveraging tertiary lymphoid structure biology. The Company has a partnership in place with Ono Pharmaceutical for two oncology targets. Underpinning MTx’s core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high-throughput screening capabilities. MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital.

Branche
Biotechnologieforschung
Größe
11–50 Beschäftigte
Hauptsitz
Schlieren, Zurich
Art
Privatunternehmen
Gegründet
2012
Spezialgebiete
Therapeutic antibodies, Infectious disease, Human antibodies, Antibody repertoire, antibodyome, High throughput, single B cell und Antibody discovery

Orte

Beschäftigte von Memo Therapeutics AG

Updates

Ähnliche Seiten

Finanzierung

Memo Therapeutics AG Insgesamt 7 Finanzierungsrunden

Letzte Runde

Serie C

22.015.012,00 $

Weitere Informationen auf Crunchbase